Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 3/29/2024
Go back to Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes
February 1, 2021 2:30 PM EST
Adamas Pharma (NASDAQ: ADMS) to Resume Trading at 2:35 p.m.
...
More
February 1, 2021 1:02 PM EST
Adamas Pharma (NASDAQ: ADMS) halted, news pending
...
More